Open-label extension study of oral Zasocitinib (TAK-279) in ulcerative colitis and Crohn's disease

Phase 2, open-label trial of zasocitinib in autoimmune colitis and Crohn's disease (3 cohorts), sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs) and adverse events of special interest (AESIs), Number of participants with clinically significant changes in vital sign values and 2 more. Started May 2025; status: recruiting.